Product Images Trulicity
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 48 images provide visual information about the product associated with Trulicity NDC 50090-6456 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label Image - lbl500906456
Logo - logo
QR Code - qr v1
Figure - trulicity ifu 0point75 injection sites back v1
Figure - trulicity ifu 0point75 injection sites front v1
Figure - trulicity ifu 1point5 injection sites back v1
Figure - trulicity ifu 1point5 injection sites front v1
Figure - trulicity ifu 3mg injection sites v1
Figure - trulicity ifu 4point5mg injection sites v1
Figure - trulicity ifu check v1
Exclamation - trulicity ifu exclamation v1
Figure - trulicity ifu expiration location v2
Figure - trulicity ifu inspect v1
Locked - trulicity ifu locked v1
Figure - trulicity ifu prepare v1
Figure - trulicity ifu remove v1
Figure - trulicity ifu sup 0point75 f2 v3
Figure - trulicity ifu sup 0point75 f3 v3
Figure - trulicity ifu sup 0point75 f4 v3
Figure - trulicity ifu sup 0point75 f5 v3
Figure - trulicity ifu sup 0point75 pen parts v3
This is a description of a medical device used for injections. The device consists of a top section and a bottom section separated by a clear base. The top section includes an injection button, a lock ring, an indicator, and a lock/unlock mechanism. The bottom section includes a needle end and a base cap. The device appears to be adjustable and customizable to suit the needs of different patients and injection types.*
Figure - trulicity ifu sup 0point75 pen v3
Figure - trulicity ifu sup 1point5 f2 v3
Figure - trulicity ifu sup 1point5 f3 v3
Figure - trulicity ifu sup 1point5 f4 v3
Figure - trulicity ifu sup 1point5 f5 v3
Figure - trulicity ifu sup 1point5 pen parts v3
This text appears to be a diagram or image showing the components of a medical injection device. It includes labels for a "Top", "Lock Ring", "Indicator", "Medicine", "Bottom/Clear Base", "Needle", and "End Cap". It is not possible to provide more detailed information without additional context or visual reference.*
Figure - trulicity ifu sup 1point5 pen v3
Figure - trulicity ifu sup 3mg f2 v1
Figure - trulicity ifu sup 3mg f3 v1
Figure - trulicity ifu sup 3mg f4 v1
This text appears to be a short message or instruction about injection and the visibility of a gray plunger to confirm completion. It is unclear what type of injection is being referred to or any other context surrounding the message.*
Figure - trulicity ifu sup 3mg f5 v1
Figure - trulicity ifu sup 3mg pen parts v1
Figure - trulicity ifu sup 3mg pen v1
Figure - trulicity ifu sup 4point5 f2 v1
Figure - trulicity ifu sup 4point5 f3 v1
Figure - trulicity ifu sup 4point5 f4 v1
This text seems to be an instruction for an injection. It mentions the "gray plunger", which is an indicator to show that the injection is complete. However, there is not enough context to determine what type of injection or where it should be administered.*
Figure - trulicity ifu sup 4point5 f5 v1
Figure - trulicity ifu sup 4point5 pen parts v1
This is a not-available description because the given text seems to be a list of words or phrases that do not convey any coherent meaning.*
Figure - trulicity ifu sup 4point5 pen v1
Figure - trulicity ifu unfold v1
Unlocked - trulicity ifu unlock v1
Figure 1 - trulicity pi f1 v2
The text seems to be a list of factors or variables related to a medical condition, possibly related to the effects of Intrinsic Factor. It includes information such as weight, age, gender, ethnicity, renal and hepatic impairments, and different levels of severity. There are also terms related to statistics or pharmacokinetics listed at the end.*
Figure 2 - trulicity pi f2 v2
Figure 3 - trulicity pi f3 v3
Figure 4 - trulicity pi f4 v3
This is a chart showing mean HbA1c (%) levels ranging from 85 to 65 and Trulicity dosage variants of 1.5mg, 3mg, and 4.5mg. The chart also includes a weeks post-randomization timeline from week 12 to week 36.*
Figure 5 - trulicity pi f5 v2
This is a clinical trial report showing the LS mean HbA1 (%) values at 26 weeks post-randomization for four different treatments including Trulicity (15mg and 0.75mg), Exenaide, and Piacabo. The HbA1 (%) values ranged from 8.0 to 6.0 across the treatments.*
Figure 6 - trulicity pi f6 v2
This is a statistical report on the effectiveness of the drug Dulaglutide in reducing the number of events in patients as compared to a placebo. The data shows that patients on Dulaglutide had a lower incidence of events with a hazard ratio (HR) of 0.88 and a confidence interval (CI) of 95%. The time in years from randomization is also presented as 6 years.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.